Annual report to the nation on the status of cancer, part I: National cancer statistics
Background The American Cancer Society, the Centers for Disease Control and Prevention, the National Cancer Institute, and the North American Association of Central Cancer Registries collaborate to provide annual updates on cancer occurrence and trends in the United States. Methods Data on new cance...
Saved in:
| Published in: | Cancer Vol. 126; no. 10; pp. 2225 - 2249 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Wiley Subscription Services, Inc
15.05.2020
|
| Subjects: | |
| ISSN: | 0008-543X, 1097-0142, 1097-0142 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Background
The American Cancer Society, the Centers for Disease Control and Prevention, the National Cancer Institute, and the North American Association of Central Cancer Registries collaborate to provide annual updates on cancer occurrence and trends in the United States.
Methods
Data on new cancer diagnoses during 2001 through 2016 were obtained from the Centers for Disease Control and Prevention‐funded and National Cancer Institute‐funded population‐based cancer registry programs and compiled by the North American Association of Central Cancer Registries. Data on cancer deaths during 2001 through 2017 were obtained from the National Center for Health Statistics' National Vital Statistics System. Trends in incidence and death rates for all cancers combined and for the leading cancer types by sex, racial/ethnic group, and age were estimated by joinpoint analysis and characterized by the average annual percent change during the most recent 5 years (2012‐2016 for incidence and 2013‐2017 for mortality).
Results
Overall, cancer incidence rates decreased 0.6% on average per year during 2012 through 2016, but trends differed by sex, racial/ethnic group, and cancer type. Among males, cancer incidence rates were stable overall and among non‐Hispanic white males but decreased in other racial/ethnic groups; rates increased for 5 of the 17 most common cancers, were stable for 7 cancers (including prostate), and decreased for 5 cancers (including lung and bronchus [lung] and colorectal). Among females, cancer incidence rates increased during 2012 to 2016 in all racial/ethnic groups, increasing on average 0.2% per year; rates increased for 8 of the 18 most common cancers (including breast), were stable for 6 cancers (including colorectal), and decreased for 4 cancers (including lung). Overall, cancer death rates decreased 1.5% on average per year during 2013 to 2017, decreasing 1.8% per year among males and 1.4% per year among females. During 2013 to 2017, cancer death rates decreased for all cancers combined among both males and females in each racial/ethnic group, for 11 of the 19 most common cancers among males (including lung and colorectal), and for 14 of the 20 most common cancers among females (including lung, colorectal, and breast). The largest declines in death rates were observed for melanoma of the skin (decreasing 6.1% per year among males and 6.3% among females) and lung (decreasing 4.8% per year among males and 3.7% among females). Among children younger than 15 years, cancer incidence rates increased an average of 0.8% per year during 2012 to 2016, and cancer death rates decreased an average of 1.4% per year during 2013 to 2017. Among adolescents and young adults aged 15 to 39 years, cancer incidence rates increased an average of 0.9% per year during 2012 to 2016, and cancer death rates decreased an average of 1.0% per year during 2013 to 2017.
Conclusions
Although overall cancer death rates continue to decline, incidence rates are leveling off among males and are increasing slightly among females. These trends reflect population changes in cancer risk factors, screening test use, diagnostic practices, and treatment advances. Many cancers can be prevented or treated effectively if they are found early. Population‐based cancer incidence and mortality data can be used to inform efforts to decrease the cancer burden in the United States and regularly monitor progress toward goals.
The Centers for Disease Control and Prevention, the American Cancer Society, the National Cancer Institute, and the North American Association of Central Cancer Registries collaborate to provide annual updates on cancer occurrence and trends in the United States and to address a special topic of interest. Part I of this report focuses on national cancer statistics, and part II characterizes progress in achieving select Healthy People 2020 objectives related to 4 common cancers. |
|---|---|
| AbstractList | The Centers for Disease Control and Prevention, the American Cancer Society, the National Cancer Institute, and the North American Association of Central Cancer Registries collaborate to provide annual updates on cancer occurrence and trends in the United States and to address a special topic of interest. Part I of this report focuses on national cancer statistics, and part II characterizes progress in achieving select Healthy People 2020 objectives related to 4 common cancers. The American Cancer Society, the Centers for Disease Control and Prevention, the National Cancer Institute, and the North American Association of Central Cancer Registries collaborate to provide annual updates on cancer occurrence and trends in the United States. Data on new cancer diagnoses during 2001 through 2016 were obtained from the Centers for Disease Control and Prevention-funded and National Cancer Institute-funded population-based cancer registry programs and compiled by the North American Association of Central Cancer Registries. Data on cancer deaths during 2001 through 2017 were obtained from the National Center for Health Statistics' National Vital Statistics System. Trends in incidence and death rates for all cancers combined and for the leading cancer types by sex, racial/ethnic group, and age were estimated by joinpoint analysis and characterized by the average annual percent change during the most recent 5 years (2012-2016 for incidence and 2013-2017 for mortality). Overall, cancer incidence rates decreased 0.6% on average per year during 2012 through 2016, but trends differed by sex, racial/ethnic group, and cancer type. Among males, cancer incidence rates were stable overall and among non-Hispanic white males but decreased in other racial/ethnic groups; rates increased for 5 of the 17 most common cancers, were stable for 7 cancers (including prostate), and decreased for 5 cancers (including lung and bronchus [lung] and colorectal). Among females, cancer incidence rates increased during 2012 to 2016 in all racial/ethnic groups, increasing on average 0.2% per year; rates increased for 8 of the 18 most common cancers (including breast), were stable for 6 cancers (including colorectal), and decreased for 4 cancers (including lung). Overall, cancer death rates decreased 1.5% on average per year during 2013 to 2017, decreasing 1.8% per year among males and 1.4% per year among females. During 2013 to 2017, cancer death rates decreased for all cancers combined among both males and females in each racial/ethnic group, for 11 of the 19 most common cancers among males (including lung and colorectal), and for 14 of the 20 most common cancers among females (including lung, colorectal, and breast). The largest declines in death rates were observed for melanoma of the skin (decreasing 6.1% per year among males and 6.3% among females) and lung (decreasing 4.8% per year among males and 3.7% among females). Among children younger than 15 years, cancer incidence rates increased an average of 0.8% per year during 2012 to 2016, and cancer death rates decreased an average of 1.4% per year during 2013 to 2017. Among adolescents and young adults aged 15 to 39 years, cancer incidence rates increased an average of 0.9% per year during 2012 to 2016, and cancer death rates decreased an average of 1.0% per year during 2013 to 2017. Although overall cancer death rates continue to decline, incidence rates are leveling off among males and are increasing slightly among females. These trends reflect population changes in cancer risk factors, screening test use, diagnostic practices, and treatment advances. Many cancers can be prevented or treated effectively if they are found early. Population-based cancer incidence and mortality data can be used to inform efforts to decrease the cancer burden in the United States and regularly monitor progress toward goals. BackgroundThe American Cancer Society, the Centers for Disease Control and Prevention, the National Cancer Institute, and the North American Association of Central Cancer Registries collaborate to provide annual updates on cancer occurrence and trends in the United States.MethodsData on new cancer diagnoses during 2001 through 2016 were obtained from the Centers for Disease Control and Prevention‐funded and National Cancer Institute‐funded population‐based cancer registry programs and compiled by the North American Association of Central Cancer Registries. Data on cancer deaths during 2001 through 2017 were obtained from the National Center for Health Statistics' National Vital Statistics System. Trends in incidence and death rates for all cancers combined and for the leading cancer types by sex, racial/ethnic group, and age were estimated by joinpoint analysis and characterized by the average annual percent change during the most recent 5 years (2012‐2016 for incidence and 2013‐2017 for mortality).ResultsOverall, cancer incidence rates decreased 0.6% on average per year during 2012 through 2016, but trends differed by sex, racial/ethnic group, and cancer type. Among males, cancer incidence rates were stable overall and among non‐Hispanic white males but decreased in other racial/ethnic groups; rates increased for 5 of the 17 most common cancers, were stable for 7 cancers (including prostate), and decreased for 5 cancers (including lung and bronchus [lung] and colorectal). Among females, cancer incidence rates increased during 2012 to 2016 in all racial/ethnic groups, increasing on average 0.2% per year; rates increased for 8 of the 18 most common cancers (including breast), were stable for 6 cancers (including colorectal), and decreased for 4 cancers (including lung). Overall, cancer death rates decreased 1.5% on average per year during 2013 to 2017, decreasing 1.8% per year among males and 1.4% per year among females. During 2013 to 2017, cancer death rates decreased for all cancers combined among both males and females in each racial/ethnic group, for 11 of the 19 most common cancers among males (including lung and colorectal), and for 14 of the 20 most common cancers among females (including lung, colorectal, and breast). The largest declines in death rates were observed for melanoma of the skin (decreasing 6.1% per year among males and 6.3% among females) and lung (decreasing 4.8% per year among males and 3.7% among females). Among children younger than 15 years, cancer incidence rates increased an average of 0.8% per year during 2012 to 2016, and cancer death rates decreased an average of 1.4% per year during 2013 to 2017. Among adolescents and young adults aged 15 to 39 years, cancer incidence rates increased an average of 0.9% per year during 2012 to 2016, and cancer death rates decreased an average of 1.0% per year during 2013 to 2017.ConclusionsAlthough overall cancer death rates continue to decline, incidence rates are leveling off among males and are increasing slightly among females. These trends reflect population changes in cancer risk factors, screening test use, diagnostic practices, and treatment advances. Many cancers can be prevented or treated effectively if they are found early. Population‐based cancer incidence and mortality data can be used to inform efforts to decrease the cancer burden in the United States and regularly monitor progress toward goals. The American Cancer Society, the Centers for Disease Control and Prevention, the National Cancer Institute, and the North American Association of Central Cancer Registries collaborate to provide annual updates on cancer occurrence and trends in the United States.BACKGROUNDThe American Cancer Society, the Centers for Disease Control and Prevention, the National Cancer Institute, and the North American Association of Central Cancer Registries collaborate to provide annual updates on cancer occurrence and trends in the United States.Data on new cancer diagnoses during 2001 through 2016 were obtained from the Centers for Disease Control and Prevention-funded and National Cancer Institute-funded population-based cancer registry programs and compiled by the North American Association of Central Cancer Registries. Data on cancer deaths during 2001 through 2017 were obtained from the National Center for Health Statistics' National Vital Statistics System. Trends in incidence and death rates for all cancers combined and for the leading cancer types by sex, racial/ethnic group, and age were estimated by joinpoint analysis and characterized by the average annual percent change during the most recent 5 years (2012-2016 for incidence and 2013-2017 for mortality).METHODSData on new cancer diagnoses during 2001 through 2016 were obtained from the Centers for Disease Control and Prevention-funded and National Cancer Institute-funded population-based cancer registry programs and compiled by the North American Association of Central Cancer Registries. Data on cancer deaths during 2001 through 2017 were obtained from the National Center for Health Statistics' National Vital Statistics System. Trends in incidence and death rates for all cancers combined and for the leading cancer types by sex, racial/ethnic group, and age were estimated by joinpoint analysis and characterized by the average annual percent change during the most recent 5 years (2012-2016 for incidence and 2013-2017 for mortality).Overall, cancer incidence rates decreased 0.6% on average per year during 2012 through 2016, but trends differed by sex, racial/ethnic group, and cancer type. Among males, cancer incidence rates were stable overall and among non-Hispanic white males but decreased in other racial/ethnic groups; rates increased for 5 of the 17 most common cancers, were stable for 7 cancers (including prostate), and decreased for 5 cancers (including lung and bronchus [lung] and colorectal). Among females, cancer incidence rates increased during 2012 to 2016 in all racial/ethnic groups, increasing on average 0.2% per year; rates increased for 8 of the 18 most common cancers (including breast), were stable for 6 cancers (including colorectal), and decreased for 4 cancers (including lung). Overall, cancer death rates decreased 1.5% on average per year during 2013 to 2017, decreasing 1.8% per year among males and 1.4% per year among females. During 2013 to 2017, cancer death rates decreased for all cancers combined among both males and females in each racial/ethnic group, for 11 of the 19 most common cancers among males (including lung and colorectal), and for 14 of the 20 most common cancers among females (including lung, colorectal, and breast). The largest declines in death rates were observed for melanoma of the skin (decreasing 6.1% per year among males and 6.3% among females) and lung (decreasing 4.8% per year among males and 3.7% among females). Among children younger than 15 years, cancer incidence rates increased an average of 0.8% per year during 2012 to 2016, and cancer death rates decreased an average of 1.4% per year during 2013 to 2017. Among adolescents and young adults aged 15 to 39 years, cancer incidence rates increased an average of 0.9% per year during 2012 to 2016, and cancer death rates decreased an average of 1.0% per year during 2013 to 2017.RESULTSOverall, cancer incidence rates decreased 0.6% on average per year during 2012 through 2016, but trends differed by sex, racial/ethnic group, and cancer type. Among males, cancer incidence rates were stable overall and among non-Hispanic white males but decreased in other racial/ethnic groups; rates increased for 5 of the 17 most common cancers, were stable for 7 cancers (including prostate), and decreased for 5 cancers (including lung and bronchus [lung] and colorectal). Among females, cancer incidence rates increased during 2012 to 2016 in all racial/ethnic groups, increasing on average 0.2% per year; rates increased for 8 of the 18 most common cancers (including breast), were stable for 6 cancers (including colorectal), and decreased for 4 cancers (including lung). Overall, cancer death rates decreased 1.5% on average per year during 2013 to 2017, decreasing 1.8% per year among males and 1.4% per year among females. During 2013 to 2017, cancer death rates decreased for all cancers combined among both males and females in each racial/ethnic group, for 11 of the 19 most common cancers among males (including lung and colorectal), and for 14 of the 20 most common cancers among females (including lung, colorectal, and breast). The largest declines in death rates were observed for melanoma of the skin (decreasing 6.1% per year among males and 6.3% among females) and lung (decreasing 4.8% per year among males and 3.7% among females). Among children younger than 15 years, cancer incidence rates increased an average of 0.8% per year during 2012 to 2016, and cancer death rates decreased an average of 1.4% per year during 2013 to 2017. Among adolescents and young adults aged 15 to 39 years, cancer incidence rates increased an average of 0.9% per year during 2012 to 2016, and cancer death rates decreased an average of 1.0% per year during 2013 to 2017.Although overall cancer death rates continue to decline, incidence rates are leveling off among males and are increasing slightly among females. These trends reflect population changes in cancer risk factors, screening test use, diagnostic practices, and treatment advances. Many cancers can be prevented or treated effectively if they are found early. Population-based cancer incidence and mortality data can be used to inform efforts to decrease the cancer burden in the United States and regularly monitor progress toward goals.CONCLUSIONSAlthough overall cancer death rates continue to decline, incidence rates are leveling off among males and are increasing slightly among females. These trends reflect population changes in cancer risk factors, screening test use, diagnostic practices, and treatment advances. Many cancers can be prevented or treated effectively if they are found early. Population-based cancer incidence and mortality data can be used to inform efforts to decrease the cancer burden in the United States and regularly monitor progress toward goals. Background The American Cancer Society, the Centers for Disease Control and Prevention, the National Cancer Institute, and the North American Association of Central Cancer Registries collaborate to provide annual updates on cancer occurrence and trends in the United States. Methods Data on new cancer diagnoses during 2001 through 2016 were obtained from the Centers for Disease Control and Prevention‐funded and National Cancer Institute‐funded population‐based cancer registry programs and compiled by the North American Association of Central Cancer Registries. Data on cancer deaths during 2001 through 2017 were obtained from the National Center for Health Statistics' National Vital Statistics System. Trends in incidence and death rates for all cancers combined and for the leading cancer types by sex, racial/ethnic group, and age were estimated by joinpoint analysis and characterized by the average annual percent change during the most recent 5 years (2012‐2016 for incidence and 2013‐2017 for mortality). Results Overall, cancer incidence rates decreased 0.6% on average per year during 2012 through 2016, but trends differed by sex, racial/ethnic group, and cancer type. Among males, cancer incidence rates were stable overall and among non‐Hispanic white males but decreased in other racial/ethnic groups; rates increased for 5 of the 17 most common cancers, were stable for 7 cancers (including prostate), and decreased for 5 cancers (including lung and bronchus [lung] and colorectal). Among females, cancer incidence rates increased during 2012 to 2016 in all racial/ethnic groups, increasing on average 0.2% per year; rates increased for 8 of the 18 most common cancers (including breast), were stable for 6 cancers (including colorectal), and decreased for 4 cancers (including lung). Overall, cancer death rates decreased 1.5% on average per year during 2013 to 2017, decreasing 1.8% per year among males and 1.4% per year among females. During 2013 to 2017, cancer death rates decreased for all cancers combined among both males and females in each racial/ethnic group, for 11 of the 19 most common cancers among males (including lung and colorectal), and for 14 of the 20 most common cancers among females (including lung, colorectal, and breast). The largest declines in death rates were observed for melanoma of the skin (decreasing 6.1% per year among males and 6.3% among females) and lung (decreasing 4.8% per year among males and 3.7% among females). Among children younger than 15 years, cancer incidence rates increased an average of 0.8% per year during 2012 to 2016, and cancer death rates decreased an average of 1.4% per year during 2013 to 2017. Among adolescents and young adults aged 15 to 39 years, cancer incidence rates increased an average of 0.9% per year during 2012 to 2016, and cancer death rates decreased an average of 1.0% per year during 2013 to 2017. Conclusions Although overall cancer death rates continue to decline, incidence rates are leveling off among males and are increasing slightly among females. These trends reflect population changes in cancer risk factors, screening test use, diagnostic practices, and treatment advances. Many cancers can be prevented or treated effectively if they are found early. Population‐based cancer incidence and mortality data can be used to inform efforts to decrease the cancer burden in the United States and regularly monitor progress toward goals. The Centers for Disease Control and Prevention, the American Cancer Society, the National Cancer Institute, and the North American Association of Central Cancer Registries collaborate to provide annual updates on cancer occurrence and trends in the United States and to address a special topic of interest. Part I of this report focuses on national cancer statistics, and part II characterizes progress in achieving select Healthy People 2020 objectives related to 4 common cancers. |
| Author | Jemal, Ahmedin Kohler, Betsy A. Ward, Elizabeth M. Islami, Farhad Henley, S. Jane Cronin, Kathleen Scott, Susan Ma, Jiemin Anderson, Robert N. Thomas, Cheryll C. Lewis, Denise Riedel Benard, Vicki B. Wu, Manxia Firth, Albert U. Richardson, Lisa C. Weir, Hannah K. Sherman, Recinda L. |
| Author_xml | – sequence: 1 givenname: S. Jane orcidid: 0000-0002-2420-306X surname: Henley fullname: Henley, S. Jane email: shenley@cdc.gov organization: Centers for Disease Control and Prevention – sequence: 2 givenname: Elizabeth M. surname: Ward fullname: Ward, Elizabeth M. organization: North American Association of Central Cancer Registries – sequence: 3 givenname: Susan orcidid: 0000-0001-5881-8313 surname: Scott fullname: Scott, Susan organization: National Institutes of Health – sequence: 4 givenname: Jiemin orcidid: 0000-0002-1101-8156 surname: Ma fullname: Ma, Jiemin organization: American Cancer Society – sequence: 5 givenname: Robert N. surname: Anderson fullname: Anderson, Robert N. organization: Centers for Disease Control and Prevention – sequence: 6 givenname: Albert U. surname: Firth fullname: Firth, Albert U. organization: Information Management Services, Inc – sequence: 7 givenname: Cheryll C. surname: Thomas fullname: Thomas, Cheryll C. organization: Centers for Disease Control and Prevention – sequence: 8 givenname: Farhad orcidid: 0000-0002-7357-5994 surname: Islami fullname: Islami, Farhad organization: American Cancer Society – sequence: 9 givenname: Hannah K. orcidid: 0000-0001-6568-9708 surname: Weir fullname: Weir, Hannah K. organization: Centers for Disease Control and Prevention – sequence: 10 givenname: Denise Riedel orcidid: 0000-0003-3385-2958 surname: Lewis fullname: Lewis, Denise Riedel organization: National Institutes of Health – sequence: 11 givenname: Recinda L. surname: Sherman fullname: Sherman, Recinda L. organization: North American Association of Central Cancer Registries – sequence: 12 givenname: Manxia surname: Wu fullname: Wu, Manxia organization: Centers for Disease Control and Prevention – sequence: 13 givenname: Vicki B. surname: Benard fullname: Benard, Vicki B. organization: Centers for Disease Control and Prevention – sequence: 14 givenname: Lisa C. surname: Richardson fullname: Richardson, Lisa C. organization: Centers for Disease Control and Prevention – sequence: 15 givenname: Ahmedin orcidid: 0000-0002-0000-4111 surname: Jemal fullname: Jemal, Ahmedin organization: American Cancer Society – sequence: 16 givenname: Kathleen surname: Cronin fullname: Cronin, Kathleen organization: National Institutes of Health – sequence: 17 givenname: Betsy A. surname: Kohler fullname: Kohler, Betsy A. organization: North American Association of Central Cancer Registries |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32162336$$D View this record in MEDLINE/PubMed |
| BookMark | eNp90VtLwzAUB_Agirvoix9AAr6I2JlLr76N4mUwJoiibyVNU-zokpqkyL69aTt9GCIEwiG__yGcMwGHUkkBwBlGM4wQueGS6xklMSIHYIxREnkI--QQjBFCsRf49H0EJsasXRmRgB6DESU4JJSGY_A2l7JlNdSiUdpCq6D9EFAyWykJ3ekqY5ltDVQl5Exyoa9hw5xd3MJV71x8eOhlZWzFzQk4KlltxOnunoLX-7uX9NFbPj0s0vnS4zTyiReFuMCMhCLGLAl4TlmAkwLxguQsx3mOccQCFic0iAOWxyTy_dLVJUliRyilU3A59G20-myFsdmmMlzUNZNCtSYjNAojEochdvRij65Vq93vO5UExHezCZ0636k234gia3S1YXqb_YzMgasBcK2M0aL8JRhl3T6ybh9Zvw-H0R7mle2HZjWr6r8jeIh8VbXY_tM8S1fp85D5BtXbmwQ |
| CitedBy_id | crossref_primary_10_1007_s00520_022_06974_y crossref_primary_10_1016_j_soc_2020_11_013 crossref_primary_10_1002_sim_10218 crossref_primary_10_3390_cancers16233918 crossref_primary_10_1093_jnci_djab096 crossref_primary_10_3389_fphar_2022_1019312 crossref_primary_10_1002_cam4_4166 crossref_primary_10_1007_s10904_025_03796_3 crossref_primary_10_3389_fonc_2023_1168769 crossref_primary_10_3390_ijms22095016 crossref_primary_10_1177_09691413221128666 crossref_primary_10_1016_j_compbiomed_2021_104571 crossref_primary_10_30802_AALAS_CM_23_000004 crossref_primary_10_3892_or_2025_8886 crossref_primary_10_7759_cureus_31502 crossref_primary_10_3389_fimmu_2021_657326 crossref_primary_10_3389_fonc_2020_568574 crossref_primary_10_1016_j_canep_2021_101938 crossref_primary_10_1177_10732748241272477 crossref_primary_10_1177_1533033820983284 crossref_primary_10_1016_j_ypmed_2020_106336 crossref_primary_10_1080_14737159_2021_1981290 crossref_primary_10_3389_fonc_2023_1177482 crossref_primary_10_1111_iji_12626 crossref_primary_10_1016_j_oret_2020_09_015 crossref_primary_10_1016_j_amjoto_2022_103491 crossref_primary_10_1039_D1RA00579K crossref_primary_10_1016_j_imu_2021_100680 crossref_primary_10_3389_fbioe_2022_996177 crossref_primary_10_1088_2053_1591_ad4cbd crossref_primary_10_1097_MPA_0000000000001603 crossref_primary_10_3390_cancers13246264 crossref_primary_10_1186_s12935_024_03264_x crossref_primary_10_2147_OTT_S281251 crossref_primary_10_1016_j_prp_2022_153990 crossref_primary_10_3390_medicina60030486 crossref_primary_10_3389_fphys_2021_609770 crossref_primary_10_7326_M20_7385 crossref_primary_10_1016_j_amjsurg_2020_12_040 crossref_primary_10_1186_s12885_021_08441_z crossref_primary_10_1093_jncics_pkac022 crossref_primary_10_3390_cancers15133522 crossref_primary_10_1186_s12877_022_03683_3 crossref_primary_10_1186_s12951_024_02605_2 crossref_primary_10_3390_pharmaceutics13101562 crossref_primary_10_1186_s12951_020_00746_8 crossref_primary_10_1002_cncr_33325 crossref_primary_10_1016_j_ccr_2022_214946 crossref_primary_10_1016_j_omto_2021_01_014 crossref_primary_10_1177_10732748211041221 crossref_primary_10_1089_jayao_2021_0233 crossref_primary_10_1088_1748_605X_abdb08 crossref_primary_10_1186_s12885_021_08979_y crossref_primary_10_3390_bios14100501 crossref_primary_10_1016_j_bbrc_2025_152146 crossref_primary_10_1016_j_jss_2022_06_031 crossref_primary_10_1016_j_suronc_2020_11_017 crossref_primary_10_1186_s12885_024_12630_x crossref_primary_10_1002_cncr_33435 crossref_primary_10_1177_03000605211058364 crossref_primary_10_3390_jcm10112429 crossref_primary_10_1038_s41598_024_60449_0 crossref_primary_10_1136_bmjopen_2022_067826 crossref_primary_10_3389_fgene_2021_723001 crossref_primary_10_1016_j_jhep_2021_08_012 crossref_primary_10_3389_fonc_2022_955771 crossref_primary_10_1177_11782234221103504 crossref_primary_10_29337_ijsonco_126 crossref_primary_10_3892_ijo_2022_5425 crossref_primary_10_3389_fonc_2021_805545 crossref_primary_10_1111_acel_13361 crossref_primary_10_1007_s00404_025_08158_5 crossref_primary_10_3389_fimmu_2024_1425212 crossref_primary_10_1158_1078_0432_CCR_22_1134 crossref_primary_10_3892_mco_2022_2490 crossref_primary_10_1007_s43032_022_01023_9 crossref_primary_10_1093_jnci_djaa093 crossref_primary_10_1590_1980_220x_reeusp_2024_0181en crossref_primary_10_1186_s41120_021_00036_z crossref_primary_10_1590_1980_220x_reeusp_2024_0181es crossref_primary_10_3390_cancers13112730 crossref_primary_10_1016_j_ijbiomac_2024_131903 crossref_primary_10_1097_CEJ_0000000000000903 crossref_primary_10_1371_journal_pone_0250939 crossref_primary_10_1016_j_cmpb_2024_108211 crossref_primary_10_1186_s12885_024_11887_6 crossref_primary_10_1016_j_cbi_2021_109673 crossref_primary_10_1016_j_diamond_2022_109149 crossref_primary_10_3390_jpm12091535 crossref_primary_10_1002_cncr_33377 crossref_primary_10_3390_antiox10030457 crossref_primary_10_2217_fon_2021_0718 crossref_primary_10_1007_s12029_024_01076_w crossref_primary_10_1007_s43032_024_01500_3 crossref_primary_10_3390_cancers14133192 crossref_primary_10_1097_MD_0000000000032797 crossref_primary_10_1016_j_ejphar_2021_174722 crossref_primary_10_1016_j_scp_2022_100675 crossref_primary_10_1002_mco2_30 crossref_primary_10_1016_j_ygyno_2022_12_017 crossref_primary_10_3390_pharmaceutics14010088 crossref_primary_10_1111_cmi_13339 crossref_primary_10_1016_j_ctarc_2021_100393 crossref_primary_10_1002_VIW_20250031 crossref_primary_10_1136_bmj_m3176 crossref_primary_10_1016_j_phymed_2022_154411 crossref_primary_10_1038_s41574_024_01003_w crossref_primary_10_1016_j_ijpharm_2021_120553 crossref_primary_10_3389_fpubh_2022_870187 crossref_primary_10_2174_1573405620666230808153145 crossref_primary_10_1016_j_jaad_2022_06_1206 crossref_primary_10_1002_jso_27041 crossref_primary_10_3390_cancers15072096 crossref_primary_10_1016_j_pmedr_2025_103180 crossref_primary_10_1093_jnci_djac038 crossref_primary_10_1016_j_compbiomed_2022_105516 crossref_primary_10_1038_s41388_021_01908_0 crossref_primary_10_1016_j_drup_2021_100762 crossref_primary_10_1016_j_ygyno_2024_01_034 crossref_primary_10_1111_jgh_15169 crossref_primary_10_3390_cancers14040985 crossref_primary_10_1097_DAD_0000000000001888 crossref_primary_10_1093_jnci_djab139 crossref_primary_10_1186_s40364_021_00336_2 crossref_primary_10_3390_cancers12092474 crossref_primary_10_1186_s12885_022_10258_3 crossref_primary_10_7759_cureus_39874 crossref_primary_10_1016_j_ygyno_2023_04_005 crossref_primary_10_1093_jnci_djab131 crossref_primary_10_3389_fonc_2021_708730 crossref_primary_10_1016_j_envint_2022_107323 crossref_primary_10_3390_ijms24044010 crossref_primary_10_5534_wjmh_210162 crossref_primary_10_3390_cancers16010185 crossref_primary_10_1016_j_canep_2022_102232 crossref_primary_10_1097_PPO_0000000000000471 crossref_primary_10_1038_s41575_020_00381_6 crossref_primary_10_1016_j_euf_2021_08_001 crossref_primary_10_1007_s00439_023_02620_7 crossref_primary_10_2147_JHC_S348785 crossref_primary_10_1007_s11060_024_04748_6 crossref_primary_10_1002_onco_13749 crossref_primary_10_1038_s41391_025_01025_z crossref_primary_10_3389_fonc_2023_1231497 crossref_primary_10_1007_s10552_021_01481_7 crossref_primary_10_1002_cam4_5304 crossref_primary_10_2188_jea_JE20200416 crossref_primary_10_1002_slct_202400777 crossref_primary_10_1097_COC_0000000000000923 crossref_primary_10_2147_JMDH_S460881 crossref_primary_10_1016_j_amjoto_2021_103270 crossref_primary_10_1186_s13019_022_02034_y crossref_primary_10_3390_cells9051091 crossref_primary_10_1002_pbc_29047 crossref_primary_10_3390_cancers12061504 crossref_primary_10_1097_NCC_0000000000001050 crossref_primary_10_1007_s12038_022_00314_2 crossref_primary_10_1016_j_ygyno_2022_11_028 crossref_primary_10_1002_bmc_5667 crossref_primary_10_2147_IJN_S329341 crossref_primary_10_1016_j_jocn_2021_06_043 crossref_primary_10_3390_jfb14070373 crossref_primary_10_1002_cncr_70029 crossref_primary_10_1001_jama_2022_8970 crossref_primary_10_3389_fonc_2022_833834 crossref_primary_10_3390_cancers12092373 crossref_primary_10_1097_EDE_0000000000001394 crossref_primary_10_1259_bjr_20210038 crossref_primary_10_1097_CEJ_0000000000000594 crossref_primary_10_3390_cells10030678 crossref_primary_10_3389_fphy_2021_636001 crossref_primary_10_1007_s00595_023_02789_4 crossref_primary_10_1016_j_anzjph_2023_100117 crossref_primary_10_1016_j_canep_2022_102254 crossref_primary_10_1155_2021_9915312 crossref_primary_10_3390_jcm14051642 crossref_primary_10_1016_j_iliver_2022_03_002 crossref_primary_10_1016_j_jaad_2022_02_063 crossref_primary_10_1016_j_molliq_2021_117202 crossref_primary_10_1002_cncr_34017 crossref_primary_10_1007_s00520_025_09152_y crossref_primary_10_1016_j_bios_2025_117247 crossref_primary_10_1016_j_cgh_2021_02_011 crossref_primary_10_1111_jcmm_16715 crossref_primary_10_1002_onco_13883 crossref_primary_10_1038_s41420_024_02186_x crossref_primary_10_2217_fon_2021_1583 crossref_primary_10_1016_j_coms_2021_11_010 crossref_primary_10_3390_cancers15041186 crossref_primary_10_1002_cncr_34008 crossref_primary_10_1016_j_bbcan_2025_189439 crossref_primary_10_1016_j_abb_2024_110287 crossref_primary_10_1016_j_eucr_2025_103034 crossref_primary_10_1016_j_intimp_2021_108016 crossref_primary_10_1097_MD_0000000000034156 crossref_primary_10_1111_bcpt_13790 crossref_primary_10_1002_cncr_34001 crossref_primary_10_1007_s40615_025_02517_3 crossref_primary_10_3390_ijms24043083 crossref_primary_10_1016_j_trre_2021_100625 crossref_primary_10_3389_fimmu_2021_764749 crossref_primary_10_1016_j_prp_2023_154987 crossref_primary_10_1016_j_canep_2021_102033 crossref_primary_10_5858_arpa_2022_0175_OA crossref_primary_10_2147_CMAR_S316428 crossref_primary_10_1007_s12672_024_01315_3 crossref_primary_10_3389_fonc_2022_818977 crossref_primary_10_1177_10781552211057486 crossref_primary_10_36290_xon_2024_004 crossref_primary_10_3390_cancers14092330 crossref_primary_10_1016_j_omton_2025_201034 crossref_primary_10_1155_2022_4466776 crossref_primary_10_1111_1475_6773_14164 crossref_primary_10_3390_cancers15041196 crossref_primary_10_1056_NEJMra2034861 crossref_primary_10_3322_caac_21654 crossref_primary_10_3390_ijms25189848 crossref_primary_10_1093_jncics_pkab065 crossref_primary_10_1002_ijgo_13942 crossref_primary_10_1016_j_ygyno_2021_02_020 crossref_primary_10_1177_03915603211036426 crossref_primary_10_1007_s00261_022_03500_w crossref_primary_10_1042_BSR20211653 crossref_primary_10_3390_medicina56070347 crossref_primary_10_1016_j_scp_2022_100606 crossref_primary_10_1007_s13235_024_00609_z crossref_primary_10_1007_s12672_025_02717_7 crossref_primary_10_3390_cells10113126 crossref_primary_10_3390_jcm14186484 crossref_primary_10_3389_fonc_2021_771579 crossref_primary_10_1038_s41391_020_00314_z crossref_primary_10_1007_s10549_021_06303_7 crossref_primary_10_1016_j_ygyno_2022_10_012 crossref_primary_10_1097_HNP_0000000000000450 crossref_primary_10_1002_anbr_202400023 crossref_primary_10_1016_j_ejmech_2021_113891 crossref_primary_10_3390_jimaging10010020 crossref_primary_10_1016_j_ygeno_2021_12_011 crossref_primary_10_1158_1078_0432_CCR_20_3407 crossref_primary_10_1016_j_amepre_2021_09_005 crossref_primary_10_1158_1940_6207_CAPR_20_0376 crossref_primary_10_1016_j_exger_2021_111587 crossref_primary_10_1002_jlcr_3906 crossref_primary_10_1186_s12889_024_17801_w crossref_primary_10_1186_s13244_022_01294_5 crossref_primary_10_1002_cam4_4315 crossref_primary_10_1016_j_jpba_2021_114134 crossref_primary_10_3389_fphar_2021_639628 crossref_primary_10_1186_s12894_023_01389_1 crossref_primary_10_1186_s12957_021_02347_7 crossref_primary_10_1186_s12905_024_02911_9 crossref_primary_10_1002_bab_2150 crossref_primary_10_1097_MCG_0000000000001649 crossref_primary_10_1093_ehjacc_zuaf027 crossref_primary_10_3390_cancers15174413 crossref_primary_10_1016_j_ygyno_2021_02_007 crossref_primary_10_1177_17588359211038478 crossref_primary_10_1016_j_intimp_2021_108337 crossref_primary_10_1002_jso_26914 crossref_primary_10_1002_adhm_202100512 crossref_primary_10_1007_s00216_023_04586_x crossref_primary_10_1016_j_jaad_2022_04_056 crossref_primary_10_1186_s12880_024_01544_6 crossref_primary_10_1093_humrep_deac029 crossref_primary_10_3389_fonc_2023_1206565 crossref_primary_10_3389_fonc_2022_857746 crossref_primary_10_1002_cncr_32805 crossref_primary_10_1007_s11060_023_04279_6 crossref_primary_10_1007_s40944_025_01006_z crossref_primary_10_1155_2021_5068228 crossref_primary_10_1002_ehf2_13647 crossref_primary_10_3390_diagnostics12030662 crossref_primary_10_2196_32728 crossref_primary_10_3390_nu16081244 crossref_primary_10_3389_fendo_2023_1059228 crossref_primary_10_3390_jpm15090417 crossref_primary_10_1002_iju5_12171 crossref_primary_10_1016_j_prp_2023_154411 crossref_primary_10_3748_wjg_v26_i45_7173 crossref_primary_10_1002_cai2_120 crossref_primary_10_1002_tox_23851 crossref_primary_10_1007_s13187_021_02060_9 crossref_primary_10_1186_s40798_020_00272_9 crossref_primary_10_1371_journal_pone_0284051 crossref_primary_10_1111_jcmm_18500 crossref_primary_10_1186_s13058_023_01609_4 crossref_primary_10_3390_ijms22042067 crossref_primary_10_3389_fonc_2021_698302 crossref_primary_10_1007_s11356_021_15938_4 crossref_primary_10_3389_fgene_2022_984615 crossref_primary_10_1016_j_cgh_2021_08_010 crossref_primary_10_1016_j_clgc_2022_12_005 crossref_primary_10_1038_s41419_020_03083_8 crossref_primary_10_1016_j_bioactmat_2024_02_009 crossref_primary_10_1038_s41598_022_12368_1 crossref_primary_10_1016_j_cpcardiol_2024_102785 crossref_primary_10_1186_s13048_023_01201_6 crossref_primary_10_1016_j_compbiomed_2023_106659 crossref_primary_10_1097_GCO_0000000000001004 crossref_primary_10_1016_j_jcmg_2021_04_001 crossref_primary_10_1007_s10552_022_01658_8 crossref_primary_10_1007_s10620_021_07274_x crossref_primary_10_1016_j_ajhg_2021_07_002 crossref_primary_10_1016_j_yexcr_2022_113214 crossref_primary_10_1177_0962280220959118 crossref_primary_10_1016_j_jgo_2022_08_020 crossref_primary_10_1007_s11010_025_05216_z crossref_primary_10_1245_s10434_023_13353_2 crossref_primary_10_1016_j_bios_2022_114715 crossref_primary_10_1182_blood_2020008971 crossref_primary_10_1038_s41391_021_00479_1 crossref_primary_10_1002_jso_26712 crossref_primary_10_1002_cam4_70062 crossref_primary_10_4103_joc_joc_53_22 crossref_primary_10_3390_diagnostics11081450 crossref_primary_10_1038_s41598_025_05460_9 crossref_primary_10_25259_Cytojournal_50_2024 crossref_primary_10_1016_j_ajcnut_2023_04_031 crossref_primary_10_3390_molecules29051168 crossref_primary_10_1016_j_jaad_2020_06_020 crossref_primary_10_1186_s12967_022_03277_y crossref_primary_10_1097_CMR_0000000000000726 crossref_primary_10_1186_s12920_023_01762_x crossref_primary_10_1016_j_microc_2024_111307 crossref_primary_10_1016_j_eururo_2022_10_020 crossref_primary_10_1007_s11901_021_00562_0 crossref_primary_10_1097_MD_0000000000030715 crossref_primary_10_1016_j_jval_2023_06_003 crossref_primary_10_1080_00365521_2020_1795922 crossref_primary_10_3390_cells14141118 crossref_primary_10_3389_fendo_2022_1065263 crossref_primary_10_1016_j_lfs_2024_122557 crossref_primary_10_1016_j_heliyon_2024_e38174 crossref_primary_10_1007_s10552_021_01461_x crossref_primary_10_1016_j_aohep_2020_06_005 crossref_primary_10_3892_mmr_2021_12481 crossref_primary_10_3389_fonc_2022_875489 crossref_primary_10_3390_cancers15123121 crossref_primary_10_3390_jcm11123472 crossref_primary_10_1002_ptr_6790 crossref_primary_10_1016_j_ejphar_2023_175983 crossref_primary_10_1053_j_gastro_2022_02_025 crossref_primary_10_1097_PGP_0000000000000864 crossref_primary_10_1002_smll_202300096 crossref_primary_10_1016_j_nano_2022_102617 crossref_primary_10_3389_fgene_2021_729046 crossref_primary_10_1038_s41598_020_72699_9 crossref_primary_10_1097_MD_0000000000042945 crossref_primary_10_3390_ijms252312974 crossref_primary_10_1186_s40959_023_00181_2 crossref_primary_10_1016_j_ejogrb_2024_05_023 crossref_primary_10_1007_s10549_021_06492_1 crossref_primary_10_1038_s41581_021_00525_0 crossref_primary_10_3389_fonc_2021_689701 crossref_primary_10_3390_medicina57040328 crossref_primary_10_1016_j_heliyon_2023_e22874 crossref_primary_10_3389_fcell_2020_622215 crossref_primary_10_1016_j_clgc_2021_11_004 crossref_primary_10_1093_tbm_ibac024 crossref_primary_10_3390_cancers14184500 crossref_primary_10_3390_ijms21093096 crossref_primary_10_3389_fphar_2021_681417 crossref_primary_10_1016_j_mtbio_2025_101654 crossref_primary_10_1002_pros_24299 crossref_primary_10_1016_j_ejso_2024_108783 crossref_primary_10_1007_s00520_025_09403_y crossref_primary_10_1177_15598276241303444 crossref_primary_10_1093_jjco_hyab139 crossref_primary_10_1097_CMR_0000000000000853 crossref_primary_10_1016_j_jconrel_2025_114028 crossref_primary_10_1016_j_cpt_2024_07_001 crossref_primary_10_1097_MNH_0000000000000819 crossref_primary_10_3390_cancers13164235 crossref_primary_10_1002_jbmr_4828 crossref_primary_10_1002_SMMD_20230035 crossref_primary_10_1016_j_actbio_2024_10_036 crossref_primary_10_1080_87559129_2021_1877300 crossref_primary_10_1007_s00520_021_06085_0 crossref_primary_10_3389_fonc_2022_925424 crossref_primary_10_7326_M21_2134 crossref_primary_10_1016_j_cgh_2021_08_032 crossref_primary_10_1016_j_arcmed_2020_09_014 crossref_primary_10_1016_j_bbrc_2025_152092 crossref_primary_10_1080_15313204_2024_2443429 crossref_primary_10_12677_jcpm_2025_43323 crossref_primary_10_1001_jamanetworkopen_2021_8356 crossref_primary_10_1016_j_chest_2020_09_252 crossref_primary_10_3389_fonc_2024_1525601 crossref_primary_10_1016_j_bulcan_2021_04_020 crossref_primary_10_1245_s10434_024_15675_1 crossref_primary_10_1002_cam4_5098 crossref_primary_10_1080_0284186X_2021_1892182 crossref_primary_10_32604_biocell_2023_027729 crossref_primary_10_1186_s12885_020_07177_6 crossref_primary_10_1002_cncr_34952 crossref_primary_10_3390_ijms23031532 crossref_primary_10_1186_s12920_022_01298_6 crossref_primary_10_1038_s41572_021_00324_8 crossref_primary_10_1007_s00520_023_07768_6 crossref_primary_10_1038_s41416_021_01624_2 crossref_primary_10_1016_j_phrs_2024_107092 crossref_primary_10_3390_ijerph18157966 crossref_primary_10_1080_2162402X_2021_1992104 crossref_primary_10_3389_fonc_2023_829054 crossref_primary_10_3390_cancers15225482 crossref_primary_10_3390_cancers16101861 crossref_primary_10_31083_j_fbl2801004 crossref_primary_10_1016_j_ctrv_2023_102531 crossref_primary_10_1007_s12029_022_00809_z crossref_primary_10_1097_MD_0000000000021869 crossref_primary_10_3389_fonc_2024_1472892 crossref_primary_10_1049_nbt2_12128 crossref_primary_10_3390_vaccines8040657 crossref_primary_10_1038_s41391_022_00526_5 crossref_primary_10_1016_j_biopha_2023_114644 crossref_primary_10_1186_s12883_021_02086_y crossref_primary_10_15585_mmwr_mm6941a1 crossref_primary_10_1016_j_medcli_2020_07_013 crossref_primary_10_1177_09636897211073136 crossref_primary_10_3390_biom12091229 crossref_primary_10_1016_j_surg_2021_10_066 crossref_primary_10_1155_2022_7761589 crossref_primary_10_1007_s00392_020_01719_5 crossref_primary_10_1001_jamanetworkopen_2021_37508 crossref_primary_10_1016_j_snb_2025_138330 crossref_primary_10_1016_j_jconrel_2023_04_006 crossref_primary_10_1016_j_toxlet_2025_111721 crossref_primary_10_3389_fmed_2022_924979 crossref_primary_10_1155_2022_3050199 crossref_primary_10_1056_NEJMra1514010 crossref_primary_10_3390_ijms23031671 crossref_primary_10_1097_DAD_0000000000001956 crossref_primary_10_1055_a_1946_5592 crossref_primary_10_1001_jamaophthalmol_2020_5720 crossref_primary_10_1111_jog_15933 crossref_primary_10_1016_j_ijcard_2024_132029 crossref_primary_10_1016_j_jid_2022_08_037 crossref_primary_10_1007_s11912_021_01160_5 crossref_primary_10_1038_s41420_020_00315_w crossref_primary_10_1186_s12014_025_09528_6 crossref_primary_10_1016_j_jpainsymman_2022_11_013 crossref_primary_10_1177_15598276221076040 crossref_primary_10_1007_s12609_020_00396_7 crossref_primary_10_1002_mp_14942 crossref_primary_10_1002_cncr_33836 crossref_primary_10_4251_wjgo_v15_i4_632 crossref_primary_10_3390_ph17020214 crossref_primary_10_3389_fonc_2022_891619 crossref_primary_10_53011_JMRO_2022_01_06 crossref_primary_10_1002_adhm_202001044 crossref_primary_10_12998_wjcc_v10_i19_6702 crossref_primary_10_3390_cancers16234035 crossref_primary_10_1016_j_medcle_2020_07_032 crossref_primary_10_1007_s44411_025_00317_z crossref_primary_10_1097_CJI_0000000000000463 crossref_primary_10_1007_s00508_020_01713_x crossref_primary_10_3389_pore_2021_582443 crossref_primary_10_1515_hsz_2022_0232 crossref_primary_10_1002_lio2_772 crossref_primary_10_1016_j_radonc_2023_109712 crossref_primary_10_1080_15592294_2022_2026591 crossref_primary_10_14701_ahbps_24_130 crossref_primary_10_1097_PAS_0000000000001806 crossref_primary_10_1007_s10637_021_01150_1 crossref_primary_10_1016_j_jaad_2022_07_062 crossref_primary_10_1016_j_ijrobp_2024_11_071 crossref_primary_10_1080_15257770_2024_2310044 crossref_primary_10_1148_radiol_2021204321 crossref_primary_10_1186_s12890_021_01800_3 crossref_primary_10_1007_s00604_020_04526_x crossref_primary_10_1186_s12920_023_01611_x crossref_primary_10_1001_jamanetworkopen_2023_50844 crossref_primary_10_1038_s41389_021_00374_3 crossref_primary_10_1245_s10434_021_11161_0 crossref_primary_10_31482_mmsl_2023_034 crossref_primary_10_1016_j_prp_2024_155203 crossref_primary_10_3390_ijerph192315654 crossref_primary_10_31083_j_fbl2907242 crossref_primary_10_3389_fimmu_2022_905259 crossref_primary_10_1242_dmm_049078 crossref_primary_10_1038_s41698_024_00673_z crossref_primary_10_3390_biomedicines11082269 crossref_primary_10_1016_j_amjsurg_2021_03_056 crossref_primary_10_1002_ddr_22010 crossref_primary_10_1007_s10916_023_01907_6 crossref_primary_10_1016_j_gore_2025_101725 crossref_primary_10_3390_pharmaceutics15041154 crossref_primary_10_1155_2021_4553832 crossref_primary_10_1016_j_canep_2021_101978 crossref_primary_10_1099_jmm_0_001744 crossref_primary_10_1007_s12032_023_02269_2 crossref_primary_10_1155_2023_8881715 crossref_primary_10_1007_s00595_022_02598_1 crossref_primary_10_1186_s40170_025_00386_2 crossref_primary_10_3390_jcm14103416 crossref_primary_10_1002_cam4_6162 crossref_primary_10_1093_ejcts_ezad203 crossref_primary_10_3389_fonc_2020_576190 crossref_primary_10_1016_j_ijbiomac_2023_127162 crossref_primary_10_2196_29763 crossref_primary_10_1002_cncr_33643 crossref_primary_10_1016_j_ejca_2021_11_024 crossref_primary_10_3390_cells14110829 crossref_primary_10_1080_10428194_2022_2131419 crossref_primary_10_1080_14756366_2024_2311157 crossref_primary_10_1053_j_gastro_2021_09_070 crossref_primary_10_3389_fimmu_2024_1441730 crossref_primary_10_1016_j_drudis_2020_07_014 crossref_primary_10_1053_j_gastro_2023_02_022 crossref_primary_10_2217_bmm_2023_0629 crossref_primary_10_1007_s12033_022_00511_2 crossref_primary_10_1016_j_lungcan_2022_08_007 crossref_primary_10_1016_j_phrs_2021_105430 crossref_primary_10_1007_s10600_022_03819_2 crossref_primary_10_3892_etm_2022_11577 |
| Cites_doi | 10.15585/mmwr.mm6254a3 10.1002/cncr.24760 10.15585/mmwr.mm6544a3 10.1002/cncr.22963 10.1056/NEJMra1703413 10.1093/jnci/djr077 10.7326/M15-2886 10.1001/jama.2018.10897 10.7326/M13-2771 10.1093/jnci/djz098 10.1001/jama.2015.14905 10.1016/j.surg.2019.01.034 10.1093/jnci/djx030 10.1542/peds.2013-3926 10.1056/NEJMsr1905447 10.1002/cncr.29258 10.3322/caac.21457 10.1093/jnci/94.20.1537 10.1002/cncr.31551 10.3322/caac.21446 10.1016/j.jpeds.2014.01.059 10.1177/003335491613100119 10.1002/cncr.28562 10.1016/j.annepidem.2018.03.001 10.1001/jama.2017.7630 10.15585/mmwr.mm6748a1 10.1158/1055-9965.EPI-19-0221 10.1016/j.ypmed.2018.05.001 10.4158/EP14466.DSCR 10.1093/jnci/djz106 10.1097/CMR.0000000000000394 10.1002/cncr.27514 10.7326/0003-4819-149-3-200808050-00008 10.1038/nrclinonc.2017.43 10.1002/cncr.29936 10.5888/pcd13.160211 10.1002/cncr.31549 10.1001/jama.2016.5989 10.7326/0003-4819-157-2-201207170-00459 10.1200/JCO.2013.53.1228 10.15585/mmwr.mm6639e1 10.5888/pcd11.130174 10.12659/MSM.892035 10.1002/pbc.26888 10.1210/jc.2016-3529 10.1089/thy.2009.0110 10.1093/jnci/djn389 10.1001/jama.2018.3710 10.1056/NEJMsr1606602 |
| ContentType | Journal Article |
| Copyright | 2020 American Cancer Society 2020 American Cancer Society. |
| Copyright_xml | – notice: 2020 American Cancer Society – notice: 2020 American Cancer Society. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7TO 7U7 C1K H94 K9. NAPCQ 7X8 |
| DOI | 10.1002/cncr.32802 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Oncogenes and Growth Factors Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Oncogenes and Growth Factors Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE AIDS and Cancer Research Abstracts MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Statistics |
| EISSN | 1097-0142 |
| EndPage | 2249 |
| ExternalDocumentID | 32162336 10_1002_cncr_32802 CNCR32802 |
| Genre | article Research Support, U.S. Gov't, P.H.S Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GeographicLocations | United States United States--US |
| GeographicLocations_xml | – name: United States – name: United States--US |
| GrantInformation_xml | – fundername: North American Association of Central Cancer Registries – fundername: National Center for Chronic Disease Prevention and Health Promotion – fundername: Centers for Disease Control and Prevention – fundername: American Cancer Society – fundername: National Cancer Institute – fundername: Intramural CDC HHS grantid: CC999999 |
| GroupedDBID | --- -~X .3N .GA 05W 0R~ 10A 1CY 1L6 1OC 24P 29B 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5VS 66C 6J9 6P2 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 85S 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AARRQ AAWTL AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABHFT ABIJN ABIVO ABJNI ABLJU ABOCM ABPPZ ABPVW ABQWH ABXGK ACAHQ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACNCT ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEIGN AEIMD AENEX AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AIACR AIAGR AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM E3Z EBS EMOBN EX3 F00 F01 F04 F5P FD6 FUBAC G-S G.N GNP GODZA GX1 H.X HBH HGLYW HHY HHZ HZ~ IH2 IX1 J0M JPC KBYEO KQQ KZ1 L7B LATKE LAW LC2 LC3 LH4 LITHE LMP LOXES LP6 LP7 LSO LUTES LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 QRW R.K ROL RWI RX1 RYL SJN SUPJJ TEORI UDS UHB V2E V8K V9Y W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WIN WJL WOHZO WQJ WRC WVDHM WXI WXSBR XG1 XPP XV2 Z0Y ZGI ZZTAW ~IA ~WT AAMMB AAYXX AEFGJ AEYWJ AGHNM AGXDD AGYGG AIDQK AIDYY CITATION O8X CGR CUY CVF ECM EIF NPM 7TO 7U7 C1K H94 K9. NAPCQ 7X8 |
| ID | FETCH-LOGICAL-c3742-761d1a26e81a95cb3a519d0cd2bab1bb117a5a893585ab82744f5a8f298d2b333 |
| IEDL.DBID | WIN |
| ISSN | 0008-543X 1097-0142 |
| IngestDate | Sun Sep 28 00:03:32 EDT 2025 Tue Oct 07 07:02:00 EDT 2025 Mon Jul 21 06:05:15 EDT 2025 Tue Nov 18 21:47:06 EST 2025 Sat Nov 29 06:58:36 EST 2025 Wed Jan 22 16:35:42 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Keywords | North American Association of Central Cancer Registries (NAACCR) and End Results (SEER) program Surveillance mortality National Program of Cancer Registries (NPCR) cancer Annual Report to the Nation Epidemiology incidence trends National Vital Statistics System (NVSS) |
| Language | English |
| License | 2020 American Cancer Society. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3742-761d1a26e81a95cb3a519d0cd2bab1bb117a5a893585ab82744f5a8f298d2b333 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-2420-306X 0000-0003-3385-2958 0000-0002-0000-4111 0000-0001-6568-9708 0000-0002-7357-5994 0000-0001-5881-8313 0000-0002-1101-8156 |
| OpenAccessLink | https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.32802 |
| PMID | 32162336 |
| PQID | 2395242536 |
| PQPubID | 2045183 |
| PageCount | 25 |
| ParticipantIDs | proquest_miscellaneous_2376728661 proquest_journals_2395242536 pubmed_primary_32162336 crossref_primary_10_1002_cncr_32802 crossref_citationtrail_10_1002_cncr_32802 wiley_primary_10_1002_cncr_32802_CNCR32802 |
| PublicationCentury | 2000 |
| PublicationDate | May 15, 2020 |
| PublicationDateYYYYMMDD | 2020-05-15 |
| PublicationDate_xml | – month: 05 year: 2020 text: May 15, 2020 day: 15 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Atlanta |
| PublicationTitle | Cancer |
| PublicationTitleAlternate | Cancer |
| PublicationYear | 2020 |
| Publisher | Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc |
| References | 2017; 318 2018; 320 2002; 94 2020; 000 2018; 124 2008; 149 2008; 100 2019; 166 2014; 134 2000 2010; 116 2019; 28 2016; 315 2016; 81 2014; 160 2009; 19 2014; 120 2014; 164 2019; 111 2014; 11 2018; 28 2017; 66 2015; 121 2016; 122 2018; 67 2018; 65 2017; 377 2019; 381 2016; 164 2019; 222 2016; 13 2018; 68 2017; 109 2011; 103 2012; 157 2015; 314 2017; 14 2015; 62 2007; 110 2018; 112 2015; 21 2016; 65 2019 2016; 375 2018 2018; 319 2015 2017; 102 2012; 118 2016; 131 2014; 32 e_1_2_8_28_1 Howlader N (e_1_2_8_7_1) 2019 e_1_2_8_24_1 e_1_2_8_47_1 e_1_2_8_26_1 e_1_2_8_49_1 National Center for Health Statistics (e_1_2_8_8_1) 2019 National Comprehensive Cancer Network (NCCN) (e_1_2_8_57_1) 2019 National Vital Statistics System (e_1_2_8_10_1) 2019 e_1_2_8_20_1 e_1_2_8_43_1 e_1_2_8_66_1 e_1_2_8_22_1 e_1_2_8_45_1 e_1_2_8_64_1 e_1_2_8_41_1 e_1_2_8_60_1 e_1_2_8_17_1 e_1_2_8_19_1 National Cancer Institute (e_1_2_8_12_1) 2019 e_1_2_8_13_1 National Cancer Institute (e_1_2_8_14_1) 2019 e_1_2_8_36_1 e_1_2_8_59_1 e_1_2_8_15_1 e_1_2_8_38_1 World Cancer Research Fund/American Institute for Cancer Research (e_1_2_8_37_1) 2018 e_1_2_8_32_1 e_1_2_8_55_1 e_1_2_8_34_1 e_1_2_8_53_1 e_1_2_8_51_1 Sherman R (e_1_2_8_5_1) 2019 Henley SJ (e_1_2_8_3_1) 2020; 000 e_1_2_8_29_1 e_1_2_8_25_1 e_1_2_8_46_1 e_1_2_8_27_1 e_1_2_8_48_1 Colby SL (e_1_2_8_63_1) 2015 e_1_2_8_2_1 e_1_2_8_4_1 National Comprehensive Cancer Network (NCCN) (e_1_2_8_56_1) 2019 Indian Health Service (e_1_2_8_11_1) 2016; 81 e_1_2_8_21_1 e_1_2_8_42_1 e_1_2_8_23_1 e_1_2_8_44_1 e_1_2_8_65_1 e_1_2_8_40_1 e_1_2_8_61_1 Fritz A (e_1_2_8_6_1) 2000 e_1_2_8_18_1 e_1_2_8_39_1 US Cancer Statistics Working Group (e_1_2_8_62_1) 2019 National Cancer Institute; Surveillance, Epidemiology, and End Results (SEER) Program (e_1_2_8_9_1) 2019 e_1_2_8_35_1 e_1_2_8_16_1 e_1_2_8_58_1 National Cancer Institute (e_1_2_8_30_1) 2019 e_1_2_8_31_1 e_1_2_8_33_1 e_1_2_8_54_1 e_1_2_8_52_1 e_1_2_8_50_1 |
| References_xml | – volume: 28 start-page: 328 year: 2018 end-page: 330 article-title: Stage‐specific incidence rates and trends of prostate cancer by age, race, and ethnicity, United States, 2004‐2014 publication-title: Ann Epidemiol – volume: 81 start-page: 20388 year: 2016 end-page: 20395 article-title: Notice of the redesignation of the Service Delivery Area for the Wampanoag Tribe of Gay Head (Aquinnah) publication-title: Fed Regis – volume: 131 start-page: 126 year: 2016 end-page: 136 article-title: Evaluating early case capture of pediatric cancers in seven central cancer registries in the United States, 2013 publication-title: Public Health Rep – volume: 124 start-page: 2785 year: 2018 end-page: 2800 article-title: Annual report to the nation on the status of cancer, part I: national cancer statistics publication-title: Cancer – volume: 109 year: 2017 article-title: Annual report to the nation on the status of cancer, 1975‐2014, featuring survival publication-title: J Natl Cancer Inst – volume: 122 start-page: 1312 year: 2016 end-page: 1337 article-title: Annual report to the nation on the status of cancer, 1975‐2012, featuring the increasing incidence of liver cancer publication-title: Cancer – volume: 319 start-page: 1901 year: 2018 end-page: 1913 article-title: Screening for prostate cancer: US Preventive Services Task Force recommendation statement publication-title: JAMA – year: 2018 – volume: 381 start-page: 1378 year: 2019 end-page: 1386 article-title: Epidemiologic signatures in cancer publication-title: N Engl J Med – volume: 28 start-page: 1563 year: 2019 end-page: 1579 article-title: Cancer progress and priorities: lung cancer publication-title: Cancer Epidemiol Biomarkers Prev – volume: 28 start-page: 56 year: 2018 end-page: 60 article-title: Survival trends among patients with metastatic melanoma in the pretargeted and the post‐targeted era: a US population‐based study publication-title: Melanoma Res – volume: 112 start-page: 199 year: 2018 end-page: 206 article-title: Colorectal cancer screening in the United States: trends from 2008 to 2015 and variation by health insurance coverage publication-title: Prev Med – volume: 134 start-page: e945 year: 2014 end-page: e955 article-title: Cancer incidence rates and trends among children and adolescents in the United States, 2001‐2009 publication-title: Pediatrics – volume: 62 start-page: 11 year: 2015 end-page: 51 article-title: Summary of notifiable noninfectious conditions and disease outbreaks: surveillance for cancer incidence and mortality—United States, 2011 publication-title: MMWR Morb Mortal Wkly Rep – volume: 94 start-page: 1537 year: 2002 end-page: 1545 article-title: Impact of reporting delay and reporting error on cancer incidence rates and trends publication-title: J Natl Cancer Inst – volume: 65 year: 2018 article-title: Do pregnancy characteristics contribute to rising childhood cancer incidence rates in the United States? publication-title: Pediatr Blood Cancer – volume: 314 start-page: 2054 year: 2015 end-page: 2061 article-title: Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations publication-title: JAMA – volume: 103 start-page: 714 year: 2011 end-page: 736 article-title: Annual report to the nation on the status of cancer, 1975‐2007, featuring tumors of the brain and other nervous system publication-title: J Natl Cancer Inst – volume: 13 start-page: E157 year: 2016 article-title: Heart disease and cancer deaths—trends and projections in the United States, 1969‐2020 publication-title: Prev Chronic Dis – volume: 149 start-page: 185 year: 2008 end-page: 191 article-title: Screening for prostate cancer: US Preventive Services Task Force recommendation statement publication-title: Ann Intern Med – volume: 100 start-page: 1672 year: 2008 end-page: 1694 article-title: Annual report to the nation on the status of cancer, 1975‐2005, featuring trends in lung cancer, tobacco use, and tobacco control publication-title: J Natl Cancer Inst – volume: 124 start-page: 2801 year: 2018 end-page: 2814 article-title: Annual report to the nation on the status of cancer, part II: recent changes in prostate cancer trends and disease characteristics publication-title: Cancer – volume: 118 start-page: 2338 year: 2012 end-page: 2366 article-title: Annual report to the nation on the status of cancer, 1975‐2008, featuring cancers associated with excess weight and lack of sufficient physical activity publication-title: Cancer – volume: 67 start-page: 1333 year: 2018 end-page: 1338 article-title: Uterine cancer incidence and mortality—United States, 1999‐2016 publication-title: MMWR Morb Mortal Wkly Rep – volume: 120 start-page: 1345 year: 2014 end-page: 1352 article-title: Annual financial impact of well‐differentiated thyroid cancer care in the United States publication-title: Cancer – year: 2019 – volume: 111 start-page: 1104 year: 2019 end-page: 1106 article-title: State variation in early‐onset colorectal cancer in the United States, 1995‐2015 publication-title: J Natl Cancer Inst – volume: 110 start-page: 1429 year: 2007 end-page: 1435 article-title: Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus‐associated cancers? publication-title: Cancer – volume: 102 start-page: 2575 year: 2017 end-page: 2583 article-title: Thyroid cancer following childhood low‐dose radiation exposure: a pooled analysis of nine cohorts publication-title: J Clin Endocrinol Metab – year: 2015 – volume: 65 start-page: 1212 year: 2016 end-page: 1218 article-title: Vital signs: disparities in tobacco‐related cancer incidence and mortality—United States, 2004‐2013 publication-title: MMWR Morb Mortal Wkly Rep – volume: 160 start-page: 330 year: 2014 end-page: 338 article-title: Screening for lung cancer: US Preventive Services Task Force recommendation statement publication-title: Ann Intern Med – volume: 000 start-page: 000 year: 2020 end-page: 000 article-title: Annual report to the nation on the status of cancer, part II: progress toward Healthy People 2020 objectives for 4 common cancers publication-title: Cancer – volume: 121 start-page: 1827 year: 2015 end-page: 1837 article-title: The past, present, and future of cancer incidence in the United States: 1975 through 2020 publication-title: Cancer – volume: 222 start-page: 1279 year: 2019 end-page: 1297 article-title: Annual report to the nation on the status of cancer, featuring cancer in men and women age 20‐49 years publication-title: J Natl Cancer Inst – volume: 318 start-page: 572 year: 2017 end-page: 574 article-title: Colorectal cancer mortality rates in adults aged 20 to 54 years in the United States, 1970‐2014 publication-title: JAMA – volume: 315 start-page: 2564 year: 2016 end-page: 2575 article-title: Screening for colorectal cancer: US Preventive Services Task Force recommendation statement publication-title: JAMA – year: 2000 – volume: 66 start-page: 1052 year: 2017 end-page: 1058 article-title: Vital signs: trends in incidence of cancers associated with overweight and obesity—United States, 2005‐2014 publication-title: MMWR Morb Mortal Wkly Rep – volume: 11 start-page: E29 year: 2014 article-title: Challenges in meeting Healthy People 2020 objectives for cancer‐related preventive services, National Health Interview Survey, 2008 and 2010 publication-title: Prev Chronic Dis – volume: 164 start-page: 1481 year: 2014 end-page: 1485 article-title: Increase in the incidence of differentiated thyroid carcinoma in children, adolescents, and young adults: a population‐based study publication-title: J Pediatr – volume: 14 start-page: 463 year: 2017 end-page: 482 article-title: Targeted agents and immunotherapies: optimizing outcomes in melanoma publication-title: Nat Rev Clin Oncol – volume: 320 start-page: 674 year: 2018 end-page: 686 article-title: Screening for cervical cancer: US Preventive Services Task Force recommendation statement publication-title: JAMA – volume: 116 start-page: 544 year: 2010 end-page: 573 article-title: Annual report to the nation on the status of cancer, 1975‐2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates publication-title: Cancer – volume: 68 start-page: 250 year: 2018 end-page: 281 article-title: Colorectal cancer screening for average‐risk adults: 2018 guideline update from the American Cancer Society publication-title: CA Cancer J Clin – volume: 21 start-page: 283 year: 2015 end-page: 291 article-title: Obesity and risk of thyroid cancer: evidence from a meta‐analysis of 21 observational studies publication-title: Med Sci Monit – volume: 377 start-page: 849 year: 2017 end-page: 861 article-title: Precision diagnosis and treatment for advanced non–small‐cell lung cancer publication-title: N Engl J Med – volume: 32 start-page: 973 year: 2014 end-page: 982 article-title: Recent clinical advances in lung cancer management publication-title: J Clin Oncol – volume: 164 start-page: 279 year: 2016 end-page: 296 article-title: Screening for breast cancer: US Preventive Services Task Force recommendation statement publication-title: Ann Intern Med – volume: 21 start-page: 686 year: 2015 end-page: 696 article-title: American Association of Clinical Endocrinologists and American College of Endocrinology disease state clinical review: the increasing incidence of thyroid cancer publication-title: Endocr Pract – volume: 19 start-page: 1167 year: 2009 end-page: 1214 article-title: Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer publication-title: Thyroid – volume: 375 start-page: 794 year: 2016 end-page: 798 article-title: Body fatness and cancer—viewpoint of the IARC Working Group publication-title: N Engl J Med – volume: 166 start-page: 69 year: 2019 end-page: 74 article-title: Clinical factors associated with worse quality‐of‐life scores in United States thyroid cancer survivors publication-title: Surgery – volume: 68 start-page: 297 year: 2018 end-page: 316 article-title: Cancer screening in the United States, 2018: a review of current American Cancer Society guidelines and current issues in cancer screening publication-title: CA Cancer J Clin – volume: 157 start-page: 120 year: 2012 end-page: 134 article-title: Screening for prostate cancer: US Preventive Services Task Force recommendation statement publication-title: Ann Intern Med – ident: e_1_2_8_4_1 doi: 10.15585/mmwr.mm6254a3 – ident: e_1_2_8_31_1 doi: 10.1002/cncr.24760 – volume-title: NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer. Version 2.2020 year: 2019 ident: e_1_2_8_57_1 – ident: e_1_2_8_16_1 doi: 10.15585/mmwr.mm6544a3 – ident: e_1_2_8_39_1 doi: 10.1002/cncr.22963 – ident: e_1_2_8_58_1 doi: 10.1056/NEJMra1703413 – ident: e_1_2_8_64_1 doi: 10.1093/jnci/djr077 – volume-title: Population Estimates Used in NCI's SEER*Stat Software year: 2019 ident: e_1_2_8_9_1 – volume: 81 start-page: 20388 year: 2016 ident: e_1_2_8_11_1 article-title: Notice of the redesignation of the Service Delivery Area for the Wampanoag Tribe of Gay Head (Aquinnah) publication-title: Fed Regis – volume-title: NCCN Clinical Practice Guidelines in Oncology: Non‐Small Cell Lung Cancer. Version 2.2020 year: 2019 ident: e_1_2_8_56_1 – ident: e_1_2_8_21_1 doi: 10.7326/M15-2886 – ident: e_1_2_8_22_1 doi: 10.1001/jama.2018.10897 – volume-title: Childhood Cancer Data Initiative (CCDI) year: 2019 ident: e_1_2_8_30_1 – ident: e_1_2_8_19_1 doi: 10.7326/M13-2771 – ident: e_1_2_8_33_1 doi: 10.1093/jnci/djz098 – ident: e_1_2_8_41_1 doi: 10.1001/jama.2015.14905 – ident: e_1_2_8_48_1 doi: 10.1016/j.surg.2019.01.034 – ident: e_1_2_8_65_1 doi: 10.1093/jnci/djx030 – volume-title: National Vital Statistics System year: 2019 ident: e_1_2_8_8_1 – ident: e_1_2_8_27_1 doi: 10.1542/peds.2013-3926 – volume-title: International Classification of Diseases for Oncology year: 2000 ident: e_1_2_8_6_1 – ident: e_1_2_8_25_1 doi: 10.1056/NEJMsr1905447 – volume-title: SEER Cancer Statistics Review, 1975‐2016 year: 2019 ident: e_1_2_8_7_1 – volume-title: SEER*Stat software, version 8.3.5 year: 2019 ident: e_1_2_8_12_1 – ident: e_1_2_8_60_1 doi: 10.1002/cncr.29258 – ident: e_1_2_8_24_1 doi: 10.3322/caac.21457 – ident: e_1_2_8_13_1 doi: 10.1093/jnci/94.20.1537 – ident: e_1_2_8_66_1 doi: 10.1002/cncr.31551 – ident: e_1_2_8_23_1 doi: 10.3322/caac.21446 – volume: 000 start-page: 000 year: 2020 ident: e_1_2_8_3_1 article-title: Annual report to the nation on the status of cancer, part II: progress toward Healthy People 2020 objectives for 4 common cancers publication-title: Cancer – ident: e_1_2_8_50_1 doi: 10.1016/j.jpeds.2014.01.059 – volume-title: US Cancer Statistics data visualizations tool, based on November 2018 submission data (1999‐2016) year: 2019 ident: e_1_2_8_62_1 – ident: e_1_2_8_29_1 doi: 10.1177/003335491613100119 – ident: e_1_2_8_49_1 doi: 10.1002/cncr.28562 – volume-title: Projections of the Size and Composition of the US Population: 2014 to 2060. Population Estimates and Projections. Current Population Reports. P25‐1143 year: 2015 ident: e_1_2_8_63_1 – ident: e_1_2_8_44_1 doi: 10.1016/j.annepidem.2018.03.001 – ident: e_1_2_8_34_1 doi: 10.1001/jama.2017.7630 – ident: e_1_2_8_35_1 doi: 10.15585/mmwr.mm6748a1 – ident: e_1_2_8_55_1 doi: 10.1158/1055-9965.EPI-19-0221 – ident: e_1_2_8_32_1 doi: 10.1016/j.ypmed.2018.05.001 – volume-title: Diet, Nutrition, Physical Activity and Cancer: A Global Perspective year: 2018 ident: e_1_2_8_37_1 – ident: e_1_2_8_46_1 doi: 10.4158/EP14466.DSCR – ident: e_1_2_8_2_1 doi: 10.1093/jnci/djz106 – volume-title: Cancer in North America: 2012‐2016. Volume One: Combined Cancer Incidence for the United States, Canada, and North America year: 2019 ident: e_1_2_8_5_1 – ident: e_1_2_8_54_1 doi: 10.1097/CMR.0000000000000394 – volume-title: Joinpoint Regression Program, version 4.7.0.0 year: 2019 ident: e_1_2_8_14_1 – volume-title: Bridged‐Race Population Estimates—Data Files and Documentation year: 2019 ident: e_1_2_8_10_1 – ident: e_1_2_8_17_1 doi: 10.1002/cncr.27514 – ident: e_1_2_8_42_1 doi: 10.7326/0003-4819-149-3-200808050-00008 – ident: e_1_2_8_53_1 doi: 10.1038/nrclinonc.2017.43 – ident: e_1_2_8_38_1 doi: 10.1002/cncr.29936 – ident: e_1_2_8_61_1 doi: 10.5888/pcd13.160211 – ident: e_1_2_8_40_1 doi: 10.1002/cncr.31549 – ident: e_1_2_8_20_1 doi: 10.1001/jama.2016.5989 – ident: e_1_2_8_43_1 doi: 10.7326/0003-4819-157-2-201207170-00459 – ident: e_1_2_8_59_1 doi: 10.1200/JCO.2013.53.1228 – ident: e_1_2_8_18_1 doi: 10.15585/mmwr.mm6639e1 – ident: e_1_2_8_26_1 doi: 10.5888/pcd11.130174 – ident: e_1_2_8_52_1 doi: 10.12659/MSM.892035 – ident: e_1_2_8_28_1 doi: 10.1002/pbc.26888 – ident: e_1_2_8_51_1 doi: 10.1210/jc.2016-3529 – ident: e_1_2_8_47_1 doi: 10.1089/thy.2009.0110 – ident: e_1_2_8_15_1 doi: 10.1093/jnci/djn389 – ident: e_1_2_8_45_1 doi: 10.1001/jama.2018.3710 – ident: e_1_2_8_36_1 doi: 10.1056/NEJMsr1606602 |
| SSID | ssj0007253 |
| Score | 2.7222445 |
| Snippet | Background
The American Cancer Society, the Centers for Disease Control and Prevention, the National Cancer Institute, and the North American Association of... The Centers for Disease Control and Prevention, the American Cancer Society, the National Cancer Institute, and the North American Association of Central... The American Cancer Society, the Centers for Disease Control and Prevention, the National Cancer Institute, and the North American Association of Central... BackgroundThe American Cancer Society, the Centers for Disease Control and Prevention, the National Cancer Institute, and the North American Association of... |
| SourceID | proquest pubmed crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2225 |
| SubjectTerms | Adolescents American Cancer Society and End Results (SEER) program Annual Report to the Nation Breast Bronchus Cancer Centers for Disease Control and Prevention, U.S Children Cross-Sectional Studies Death Diagnostic systems Disease control epidemiology Female Females Health risk assessment Health risks Humans Incidence Lung cancer Lungs Male Males Melanoma Minority & ethnic groups Mortality Mortality - trends National Cancer Institute (U.S.) National Program of Cancer Registries (NPCR) National Vital Statistics System (NVSS) Neoplasms - epidemiology Neoplasms - ethnology Neoplasms - mortality North American Association of Central Cancer Registries (NAACCR) Oncology Population changes Prevention Prostate Registries Risk analysis Risk factors Sex Sex Characteristics Statistical analysis Statistics Surveillance Trends United States - epidemiology United States - ethnology Vital statistics Young adults |
| Title | Annual report to the nation on the status of cancer, part I: National cancer statistics |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcncr.32802 https://www.ncbi.nlm.nih.gov/pubmed/32162336 https://www.proquest.com/docview/2395242536 https://www.proquest.com/docview/2376728661 |
| Volume | 126 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library - Journals customDbUrl: eissn: 1097-0142 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0007253 issn: 0008-543X databaseCode: DRFUL dateStart: 19960101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Free Content customDbUrl: eissn: 1097-0142 dateEnd: 20241209 omitProxy: false ssIdentifier: ssj0007253 issn: 0008-543X databaseCode: WIN dateStart: 19960101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSwMxEB58IV58P-qjRPSiuLZJuklWvEi1KGgRUextSdLdk2yltf5-M8l2RRRBhD3skglZMjOZbzLkC8Bhn1MRO1gQcRe_oxbP8sgYziOdt4ywmWxa6zV9K7td1esl91NwPjkLE_ghqg039Ay_XqODazNqfJKG2sIOTzlTnkmStiheX_B8062WYclKCsqmiuIW71XcpKzx2fVrNPoGMb8iVh9yOkv_-9llWCyhJrkItrECU1mxCvN3ZTF9DZ4Dtz4JZQPyNiAODJKwO0jcg1943mg8IoOcWDSP4Ql5dbZGbs5ISaj9UjZ4yUD6vA5PnavH9nVU3rMQWe4y40gK2qeaiUxRncTWcO1gXb9p-8xoQ42hVOpYK6yYxtoo5BTM3XfOEuVEOOcbMFMMimwLiLDUpbwWWeSEC49CiZjKZq5FnshMC1aDo8l8p7YkIce7MF7SQJ_MUpyp1M9UDQ4q2ddAvfGj1O5EbWnpfqOU8STGXIqLGuxXzc5xsBqii2wwRhkpJFMOn9RgM6i7GoYz6mAh9j72Wv1l_LTdbT_4t-2_CO_AAsPMHXlg412YeRuOsz2Ys-9OVcM6TMueqsPs5UPn6bbu7foDcOf18g |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEB5ERb34fqzPiF4Uq5tkm6TeZFFcXIuI4t5Kkm1PS1dW199vpokVUQQRemjIhJTMTPJNpvkCcNjnVMQOFkTcrd9Ri-dFZAznkS5aRthcNq2tNN2Vaap6veQu_JuDZ2E8P0S94YaeUc3X6OC4IX32yRpqSzs65UwhleRUyyENvLnhqZPWE7FkgYSyqaK4xXs1Oyk7-2z7dT36BjK_YtZq0bla-OfnLsJ8QJvkwpvHEkzk5TLM3IZ8-go8eXp94jMH5HVIHB4kfoOQuAdLeORo_EKGBbFoIaMT8uzMjXTOSeDUHoSKStLzPq_C49XlQ_s6ClctRJa74DiSgvapZiJXVCexNVw7ZNdv2j4z2lBjKJU61gqTprE2CmkFC1cuWKKcCOd8DSbLYZlvABGWuqjXIpGccCukUCKmslloUSQy14I14OhjwDMbeMjxOoxB5hmUWYYjlVUj1YCDWvbZs2_8KLX9obcseOBLxngSYzjFRQP262rnO5gQ0WU-HKOMFJIpB1EasO71XXfDGXXIEFsfV2r9pf-snbbvq7fNvwjvwez1w20363bSmy2YYxjIIy1svA2Tr6NxvgPT9s2pbbRbmfU7Ujz3iA |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dT9swED9N7YR4YeNrdOPDCF42LWttN7azN1SoQJQKoSH6FtmO84TSqrT8_fhiE4Q2TUJIeYjlsxz57nw_--KfAY4LTkXqYUHCffxO-tyViTGcJ7rsG2Gd7Flba3okx2M1mWTX8d8cPAsT-CGaDTf0jHq-Rgd3s6LsvrCG2srOf3GmkEqy3cdbZFrQPr0Z3o6aqViySEPZU0na55OGn5R1X1q_jkh_wczXqLUOO8NP7_zgz7AW8SY5CQayDh9ctQErVzGjvgl3gWCfhNwBWUyJR4QkbBES_2AJDx0tH8i0JBZtZP6TzLzBkYvfJLJq38eKWjIwP2_B7fDsz-A8iZctJJb75XEiBS2oZsIpqrPUGq49tit6tmBGG2oMpVKnWmHaNNVGIbFg6csly5QX4ZxvQ6uaVm4HiLDUr3stUskJHyOFEimVvVKLMpNOC9aB788DntvIRI4XYtzngUOZ5ThSeT1SHThqZGeBf-OfUrvPesujDz7kjGcpLqi46MBhU-29B1MiunLTJcpIIZnyIKUDX4K-m244ox4bYusftVr_038-GA9u6revbxE-gJXr02E-uhhffoNVhit55IVNd6G1mC_dHny0j15r8_1o10_dcfgx |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Annual+report+to+the+nation+on+the+status+of+cancer%2C+part+I%3A+National+cancer+statistics&rft.jtitle=Cancer&rft.au=Henley%2C+S+Jane&rft.au=Ward%2C+Elizabeth+M&rft.au=Scott%2C+Susan&rft.au=Ma%2C+Jiemin&rft.date=2020-05-15&rft.eissn=1097-0142&rft.volume=126&rft.issue=10&rft.spage=2225&rft_id=info:doi/10.1002%2Fcncr.32802&rft_id=info%3Apmid%2F32162336&rft.externalDocID=32162336 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-543X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-543X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-543X&client=summon |